Case File
efta-efta01201757DOJ Data Set 9OtherDS9 Document EFTA01201757
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01201757
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
To: Jeffrey Epstein <[email protected]>
Subject: James MeiskenJDavid Carter
Date: Wed, 29 Oct 2014 13:38:59 +0000
Attachments: DaCart_Presentation Jul 7 2014.pdf
Begin forwarded message:
From: "James Meiskin" <
Subject: FW: Confidential
Date: October 29, 2014 at 8:15:01 AM EDT
To:
Reply-To:
M,
I attached the updated deck for JE's review. David Carter would like to meet Jeffrey over the next several weeks if
possible, and I think that they would have much in common on many levels, and that Jeffrey would find the meeting to
be worthwhile. Please let me know. Thank you. James
Dear James,
Like I have said in an earlier email. I am looking for an "investing partner" to match (50%/50%) the money Russian
Venture Capital plans to invest in USA based Biotechnology. They will provide half of the capital to develop a variety of
technologies that are of interest to their country. For their investment they get commercialization rights to the
technologies they finance for Russia and the CIS. For us, on the USA side, this is a major source of capital to start a
series of companies that have great potential as therapeutic technologies, and we get commercialization rights for the
USA, and rest of the world markets. Basically, we get the rights that are valuable to us at "half price".
Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has
already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have
several more currently in diligence. (The original Investor Presentation made in Moscow is attached)
So, I am looking for a source of capital that thinks this is an interesting investment theme, and is willing to consider the
idea as something they might want to implement. My belief is that there is more money in NYC, seeking an investment
home, then there are "quality investment ideas". I could be wrong, but I have to believe that people running a lot of
capital in New York would want to hear new, creative, and GOOD new investment ideas. I think this idea is the kind of
idea that is worth a look, and worth serious consideration. I think we are talking $150M over a five year horizon.
Best, David
David W. Carter
President—DaCart Capital LLC
EFTA01201757
EFTA01201758
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.